MCRB Stock Summary and Trading Ideas (Seres Therapeutics | NASDAQ:MCRB)

Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.

Seres Therapeutics trades on the NASDAQ stock market under the symbol MCRB.

As of September 17, 2026, MCRB stock price climbed to $4.30 with 12,032 million shares trading.

MCRB has a beta of 0.84, meaning it tends to be less sensitive to market movements. MCRB has a correlation of 0.02 to the broad based SPY ETF.

MCRB has a market cap of $43.19 million. This is considered a Sub-Micro Cap stock.

Last quarter Seres Therapeutics reported $736,000 in Revenue and $.47 earnings per share. This beat revenue expectation by $557,000 and exceeded earnings estimates by $2.63.

In the last 3 years, MCRB traded as high as $56.90 and as low as $4.18.

The top ETF exchange traded funds that MCRB belongs to (by Net Assets): VTI, VXF, SCHA, IWC, PRFZ.

MCRB has underperformed the market in the last year with a price return of -75.3% while the SPY ETF gained +16.4%. MCRB has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -28.0% and -22.4%, respectively, while the SPY returned +1.6% and -0.6%, respectively.

MCRB support price is $3.98 and resistance is $4.44 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MCRB shares will trade within this expected range on the day.